APPROACHES ACP Specialist Program vs Control: Hospice Enrollment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.147	0.139	0.155	wilson	ClinicalTrials.gov
Risk in group 2	0.161	0.152	0.169	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.014	-0.0256	-0.0024	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.913	0.846	0.985	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.898	0.821	0.982	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on APPROACHES ACP Specialist Program than on Control	71.4	39.1	417	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: control.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	APPROACHES ACP Specialist Program	Enrolled facilities that will be trained in the APPROACHES Advance Care Planning (ACP) Specialist Program.~APPROACHES ACP Specialist Program: The APPROACHES Advance Care Planning (ACP) Specialist will work with nursing home leaders (in intervention arm facilities) to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP Specialist Program with patients who have Alzheimer's disease/related dementias and their family caregivers.	1,095	7,474	OG000	ClinicalTrials.gov
Group 2	Control	Enrolled facilities that will perform standard of care Advance Care Planning (ACP) procedures.~Standard of care: Standard of care Advance Care Planning (ACP) procedures	1,181	7,358	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	SECONDARY	ClinicalTrials.gov
Title	Hospice Enrollment	ClinicalTrials.gov
Description	% ADRD patients who use hospice	ClinicalTrials.gov
Time frame	12 months	ClinicalTrials.gov
Population	Only the residents who were identified by our definition as being diagnosed with ADRD are included in our outcomes analyses.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support	ClinicalTrials.gov
NCT number	NCT03323502	ClinicalTrials.gov
Phases	NA	ClinicalTrials.gov
Conditions	Alzheimer Disease, Dementia	ClinicalTrials.gov
Interventions	APPROACHES ACP Specialist Program, Standard of care	ClinicalTrials.gov
Lead sponsor	Indiana University	ClinicalTrials.gov
Results first posted	2025-08-26	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT03323502?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.